Bioequivalence Trial of a New Opioid Combination Compared to Reference
NCT00460785 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32
Last updated 2007-07-06
Summary
The purpose of this study is to demonstrate bioequivalence of a new formulation to a reference
Conditions
- Healthy
Interventions
- DRUG
-
Opioid
Sponsors & Collaborators
-
Grünenthal GmbH
lead INDUSTRY
Principal Investigators
-
Wolfgang Timmer, Dr. · CRS Mannheim
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2007-02-28
- Completion
- 2007-03-31
More Related Trials
-
A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
NCT01100086 ·Status: COMPLETED ·Phase: PHASE1
-
To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities
NCT01101321 ·Status: COMPLETED ·Phase: PHASE1
-
Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations
NCT00387777 ·Status: TERMINATED ·Phase: PHASE1
-
OTR Tablet 10 mg Fasted-state Bioequivalence Study
NCT03403504 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
NCT01099709 ·Status: COMPLETED ·Phase: PHASE1
-
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults
NCT03137030 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
NCT01100320 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions
NCT00857142 ·Status: COMPLETED ·Phase: PHASE1
-
To Evaluate the Relative Abuse Potential of Hydrocodone Bitartrate and Acetaminophen
NCT03567941 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Between Integrated E-TRANS (Fentanyl) System and Separated (Two-Part) E-TRANS (Fentanyl) System
NCT00990418 ·Status: COMPLETED ·Phase: PHASE1
-
OTR Tablet 40 mg Fed-state Bioequivalence Study
NCT03398330 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain
NCT01081912 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
NCT01101191 ·Status: COMPLETED ·Phase: PHASE1
-
OTR Tablet 40 mg Fasted-state Bioequivalence Study
NCT03398278 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities
NCT01101308 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions
NCT01210638 ·Status: COMPLETED ·Phase: PHASE1
-
A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers
NCT01677065 ·Status: COMPLETED
-
Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time
NCT01240863 ·Status: COMPLETED ·Phase: PHASE3
-
Bioequivalence Study of Co-codamol 15mg/500mg Capsules vs Co-codamol 30mg/500mg Tablets in Healthy Subjects
NCT03280095 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain
NCT02716857 ·Status: COMPLETED ·Phase: PHASE3
-
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults
NCT03137017 ·Status: WITHDRAWN ·Phase: PHASE1
-
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
NCT00983385 ·Status: COMPLETED ·Phase: PHASE3
-
A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet
NCT01758978 ·Status: COMPLETED ·Phase: PHASE1
-
Open-Label Trial Comparing Oxycodone Medications
NCT01162304 ·Status: TERMINATED ·Phase: PHASE4
-
Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted Conditions
NCT02059915 ·Status: COMPLETED ·Phase: PHASE1